fbpx

Multiple Myeloma Knowledge Hub

CAR T-cell

Approaches to Expand CAR T-Cell Therapy to Solid Tumors

Chimeric antigen receptor (CAR) T-cell therapy has been very effective against a growing number of hematologic malignancies, including diffuse large B-cell lymphoma, B-cell acute...

Survey Defines COVID’s Impact on Delivery of CAR T-Cell Therapy in Europe

A recent letter to Bone Marrow Transplantation describes results of a survey that aimed to capture the impact of the COVID-19 pandemic’s first wave,...

Applying CAR T-Cell Therapy to Fight Malignant Mesothelioma

Malignant mesothelioma is a treatment-resistant type of cancer that starts in the mesothelial lining of the pleura or the abdominal cavity. Patients with this...

Oncology News Roundup: Dr. Mohyuddin Discusses IMW 2021, and More!

Each week on DocWire News, editors bring you the latest hematology and oncology news and research. In case you missed it, here are this week’s...

Blood Cancer Awareness Month Spotlights Hematologic Cancers

Did you know September is Blood Cancer Awareness Month? This month, take the time to learn more about this disease, which impacts more than...

Risk Factors and Incidence of Acute Kidney Injury in Patients Receiving CAR-T Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy is a major advancement in the personalized treatment of hematological malignancies, and it is being explored in the...

The Role of Medical Imaging in Managing Patients Receiving CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy has provided a novel, effective treatment option for patients with relapsed or refractory non-Hodgkin lymphoma. However, many patients...
Advertisement

Journal Reading List

Advertisement
Advertisement